Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
Seiichiro Katagiri,Nahoko Furuya,Daigo Akahane,SungGi Chi,Yosuke Minami,Yuka Harada,Hironori Harada,Akihiko Gotoh
DOI: https://doi.org/10.2147/OTT.S417137
IF: 4
2023-07-12
OncoTargets and Therapy
Abstract:Seiichiro Katagiri, 1 Nahoko Furuya, 1 Daigo Akahane, 1 SungGi Chi, 2 Yosuke Minami, 2 Yuka Harada, 3 Hironori Harada, 4 Akihiko Gotoh 1 1 Department of Hematology, Tokyo Medical University, Tokyo, Japan; 2 Department of Hematology, National Cancer Center Hospital East, Chiba, Japan; 3 Department of Clinical Laboratory, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan; 4 Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan Correspondence: Seiichiro Katagiri, Department of Hematology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan, Tel +81-3-3342-6111 (ext. 5895), Fax +81-3-5381-6651, Email We performed sequential molecular analyses of a 75-year-old woman with de novo FLT3 -ITD positive acute myeloid leukemia (AML) who had received gilteritinib therapy for 43 months. At the time of diagnosis, her karyotype was normal; however, FLT3 -ITD, NPM1, DNMT3A , and IDH2 mutations were detected. She received induction therapy with daunorubicin and cytarabine and achieved hematological complete remission (HCR). After attaining HCR, she underwent consolidation therapy with azacytidine or cytarabine, aclarubicin, and granulocyte-colony stimulating factor. However, AML relapsed eight months after the first HCR. FLT3 -ITD and NPM1 mutations were persistently positive, and the patient received gilteritinib therapy. Although the FLT3 -ITD clone was not detected during gilteritinib treatment, a clone harboring monosomy 7 and CBL mutations emerged. Bone marrow examinations at 15, 24, and 32 months after gilteritinib treatment revealed multi-lineage blood cell dysplasia without an increase in myeloblasts. After 33 months of treatment, gilteritinib was discontinued for two months because to ileus development, and the FLT3 -ITD clone was detected again. Gilteritinib treatment was restarted, and FLT3 -ITD became negative. Our analysis demonstrated that: (1) hematopoiesis derived from gilteritinib-resistant clones was generated by long-term gilteritinib treatment, and (2) FLT3 -ITD clones regained clonal dominance in the absence of FLT3 inhibition. These findings suggest that gilteritinib affects the selection of dominant clones during clonal hematopoiesis. Keywords: gilteritinib, FLT3 -ITD, CBL , monosomy 7, clonal hematopoiesis Clonal hematopoiesis is defined that the presence of a population of cells derived from a mutated multipotent stem/progenitor cell harboring a selective growth advantage in the absence of unexplained cytopenia, hematological cancers, or other clonal disorders by the 5th edition of the World Health Organization Classification. 1 It has been reported that clonal hematopoiesis increases the risk of developing myeloid neoplasms such as myelodysplastic syndromes and acute myeloid leukemia (AML). 2,3 FMS-like tyrosine kinase 3 ( FLT3 ) gene is a receptor-type tyrosine kinase, and in AML, it undergoes internal tandem duplication (ITD) mutation that duplicate and repeat part of the juxta membrane region, and tyrosine kinase domain (TKD) mutations that are point mutations in the kinase region. 4 In particular, FLT3 -ITD is an important prognostic factor in AML, and long-term survival is difficult to achieve in FLT3 -ITD-positive AML patients who cannot undergo hematopoietic stem cell transplantation (HSCT). 5 Gilteritinib is an oral, potent, selective FLT3 inhibitor with inhibitory activity against both FLT3 -ITD and FLT3 -TKD mutations, 6 and has shown significant therapeutic efficacy in relapsed refractory FLT3 -mutated AML. 6,7 Gilteritinib is expected to be a therapeutic option for transplant-ineligible patients; however, the effect of long-term administration of gilteritinib on hematopoiesis is unknown. In this study, we analyzed the changes in hematopoietic clones from diagnosis to 43 months after gilteritinib treatment in an older patient with recurrent FLT3 -ITD positive AML who received long-term administration of gilteritinib. A 75-year-old woman with fever was referred to our hospital and diagnosed with AML. Bone marrow (BM) examination revealed myeloperoxidase-positive leukemic cells and extensive BM necrosis (Figure 1A–C). Cytogenetic analysis of 24 metaphases showed a normal karyotype; however, molecular analysis of the patient by next-generation sequencing (NGS) conducted in Hematologic Malignancy (HM)-SCREEN-Japan-01 (UMIN000035233) 8 identified FLT3 -ITD, DNMT3A, IDH2 , and NPM1 mutations -Abstract Truncated-
oncology,biotechnology & applied microbiology